Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, registered for an initial public offering Friday afternoon. Bear Stearns and Credit Suisse are listed as the joint book runners on the deal. Terms and timing have yet to be announced.
